Health Sciences Acquisitions Corp (IMVTU)

Sector:
FINANCE
Industry:
GENERAL FINANCE
SIC:
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
CEO:
Peter Salzmann
Employees:
120
320 WEST 37TH STREET, NEW YORK, NY 10018
917-580-3099

*** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. IMVT-1401 is in Phase IIa clinical trials for the. treatment of myasthenia gravis and thyroid eye disease. The company is headquartered in New York, New York.

Data derived from most recent annual or quarterly report
Market Cap Avg 30-day Volume 2.822 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-1.15
Price to Revenue0.0 Debt to Equity0.0 EBITDA-156.688 Million
Price to Book Value1.2863 Operating Margin0.0 Enterprise Value110.516 Million
Current Ratio11.521 EPS Growth0 Quick Ratio11.367
1 Yr BETA -0.5852 52-week High/Low 0.0 / Profit Margin0.0
Operating Cash Flow Growth0.0 Altman Z-Score7.0491 Free Cash Flow to Firm 0

Are you looking for this stock instead?

View SEC Filings from IMVTU instead.

View recent insider trading info

Funds Holding IMVTU (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding IMVTU

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

ROIVANT SCIENCES LTD.

  • 10% Owner
56,367,388 2020-09-17 0

ELLIOTT MICHAEL JAMES CHIEF SCIENTIFIC OFFICER

  • Officer
0 2020-09-04 0

MIGAUSKY GEORGE V

  • Director
44,700 2020-05-15 0

MIDDLEKAUFF W BRADFORD GENERAL COUNSEL

  • Officer
0 2020-05-15 0

FROMKIN ANDREW J.

  • Director
24,700 2020-05-15 0

PANDE ATUL

  • Director
24,700 2020-05-15 0

TORTI FRANK

  • Director
28,400 2020-05-15 0

HUGHES DOUGLAS J.

  • Director
24,700 2020-05-15 0

BUTCHKO JULIA G. CHIEF DEV. & TECH. OFFICER

  • Officer
0 2020-05-15 0

SALZMANN PETER CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
0 2020-05-15 0

YANCHIK CONNEALY PAMELA CHIEF FINANCIAL OFFICER

  • Officer
0 2020-05-15 0

VENKER ERIC

  • Director
0 2020-02-18 0

POTTER MYRTLE S

  • Director
0 2019-12-18 0

ZELDIN ROBERT K CHIEF MEDICAL OFFICER

  • Officer
0 2019-12-18 0

HEALTH SCIENCES HOLDINGS, LLC

  • 10% Owner
No longer subject to file 2019-12-18 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

No recent transactions

*** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

Elevate your investments